Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.6
4.7
Journals
Antibodies
Special Issues
Cancer Antibodies
share announcement

Cancer Antibodies

A special issue of Antibodies (ISSN 2073-4468).

Deadline for manuscript submissions: closed (15 September 2017) | Viewed by 24314

Special Issue Editor

Dr. Armin Sepp

E-Mail
Guest Editor
Scientific Leader and GSK Associate Fellow, Systems Modeling and Translational Biology, Glaxo Medicines Research Centre 1F307, Gunnels Wood Road, GlaxoSmithKline Plc, Stevenage SG1 2NY, UK
Interests: immunotherapy; pharmacokinetics; therapeutic antibody; drug development

Special Issue Information

Dear Colleagues,

Cancer therapeutic antibodies rank among the most widely prescribed medicines in the world. Those currently approved are mostly based on a fully human (or humanized) IgG framework and target a single tumour-associated molecule on the cell surface or in solution. Despite clear clinical benefit, huge areas of unmet medical needs remain. Advances made in tumour biology, immunity and antibody engineering have opened up new therapeutic possibilities for the next generation of cancer antibodies

In this context, I suggest reviewing the following topics:

  • Checkpoint regulators and the combinations thereof. The first generation one-mAb-one-target paradigm struggles in the face of tumour heterogeneity and evolution. In contrast, the checkpoint regulator mAbs aim to reactivate the patient’s own cellular immune response in tumour microenvironment in an effort to eradicate tumour cells displaying any neoantigens, hence potentially benefiting a much wider range of patients.
  • T cell engagers: Bispecific engineered antibody-based molecules aim to re-direct and trigger response of cytotoxic T cells of any specificity by cross-linking them to the tumour cells displaying a specific surface protein target or a MHC–peptide complex. The latter opens the way for antibody-mediated therapies directed at intracellular
  • CARs and TRUCKs: tumour-specific antibody fragments displayed on engineered cytotoxic T cell surface
  • Bispecific antibodies for more nuanced tumour cell targeting where binding is limited only to cells expressing a combination of two different targets, not just one or the other. As a result, significantly reduced off-target bystander cell damage can be expected.

Dr. Armin Sepp
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • therapeutic antibodies
  • bispecific antibodies
  • checkpoint regulators
  • cytotoxic T cells

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

918 KiB  
Review
Therapeutic and Diagnostic Antibodies to CD146: Thirty Years of Research on Its Potential for Detection and Treatment of Tumors
by Jimmy Stalin, Marie Nollet, Françoise Dignat-George, Nathalie Bardin and Marcel Blot-Chabaud
Antibodies 2017, 6(4), 17; https://doi.org/10.3390/antib6040017 - 05 Nov 2017
Cited by 16 | Viewed by 7444
Abstract
CD146 (MCAM, MUC18, S-Endo1) is a transmembrane glycoprotein belonging to both CAM and mucin families. It exists as different splice variants and is cleaved from the membrane by metalloproteases to generate a soluble form. CD146 is expressed by numerous cancer cells as well [...] Read more.
CD146 (MCAM, MUC18, S-Endo1) is a transmembrane glycoprotein belonging to both CAM and mucin families. It exists as different splice variants and is cleaved from the membrane by metalloproteases to generate a soluble form. CD146 is expressed by numerous cancer cells as well as being one of the numerous proteins expressed by the vascular endothelium. It has also been identified on smooth muscle cells, pericytes, and some immune cells. This protein was initially described as an actor involved in tumor growth and metastatic dissemination processes. Some recent works highlighted the role of CD146 in angiogenesis. Interestingly, this knowledge allowed the development of therapeutic and diagnostic tools specifically targeting the different CD146 variants. The first anti-CD146 antibody designed to study the function of this molecule, MUC18, was described by the Pr. J.P. Jonhson in 1987. In this review, we will discuss the 30 following years of research focused on the detection, study, and blocking of this protein in physiological and pathological processes. Full article
(This article belongs to the Special Issue Cancer Antibodies)
►▼ Show Figures

Figure 1

4410 KiB  
Review
Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy
by Agathe Dubuisson and Olivier Micheau
Antibodies 2017, 6(4), 16; https://doi.org/10.3390/antib6040016 - 25 Oct 2017
Cited by 57 | Viewed by 16462
Abstract
Developing therapeutics that induce apoptosis in cancer cells has become an increasingly attractive approach for the past 30 years. The discovery of tumor necrosis factor (TNF) superfamily members and more specifically TNF-related apoptosis-inducing ligand (TRAIL), the only cytokine of the family capable of [...] Read more.
Developing therapeutics that induce apoptosis in cancer cells has become an increasingly attractive approach for the past 30 years. The discovery of tumor necrosis factor (TNF) superfamily members and more specifically TNF-related apoptosis-inducing ligand (TRAIL), the only cytokine of the family capable of eradicating selectively cancer cells, led to the development of numerous TRAIL derivatives targeting death receptor 4 (DR4) and death receptor 5 (DR5) for cancer therapy. With a few exceptions, preliminary attempts to use recombinant TRAIL, agonistic antibodies, or derivatives to target TRAIL agonist receptors in the clinic have been fairly disappointing. Nonetheless, a tremendous effort, worldwide, is being put into the development of novel strategic options to target TRAIL receptors. Antibodies and derivatives allow for the design of novel and efficient agonists. We summarize and discuss here the advantages and drawbacks of the soar of TRAIL therapeutics, from the first developments to the next generation of agonistic products, with a particular insight on new concepts. Full article
(This article belongs to the Special Issue Cancer Antibodies)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop